MMF, Daclizumab and Corticosteroids as Mainstay Immunosuppression in Renal Transplant Patients
Evaluating Safety and Efficacy of MMF, Daclizumab and Corticosteroids as Mainstay Immunosuppression in Combination With Low-Dose CsA, Tac or Sir in Comparison to Current Standard Immunosuppression (MMF, CsA and Corticosteroids) in Renal Tx
Sponsor: Ekberg, Henrik, M.D.
Listed as NCT00231764, this PHASE4 trial focuses on Kidney Transplantation and remains completed. Sponsored by Ekberg, Henrik, M.D., it has been updated 5 times since 2002, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE4
First recorded
Nov 2002
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ekberg, Henrik, M.D.
- Hoffmann-La Roche
- Prof. Flavio Vincenti, San Francisco, USA (Ass. Steering Committee Member)
- Prof. Josep Grinyo, Barcelona, Spain (Ass. Steering Committee Member)
- Prof. Philip Halloran, Edmonton, Canada (sponsor)
- Prof. Pierre Daloze, Montréal, Canada (Steering Committee Member)
- Prof. Thomas C. Pearson, Atlanta, USA (Steering Committee Member)
- Prof. Ulrich Frei, Berlin, Germany (Steering Committee Member)
- Prof. Yves Vanrenterghem, Leuven, Belgium (Steering Committee Member)
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.